Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
#1PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Heart failure with preserved ejection fraction · Obesity · tirzepatide · glucose-dependent insulinotropic polypeptide receptor agonist · GLP-1 receptor agonist · Cardiovascular events · weight loss · Body mass index · Cardiovascular death · Worsening heart failure events · Kansas City Cardiomyopathy Questionnaire · Patient-reported outcomes · Placebo-controlled trial · Left ventricular ejection fraction · Subcutaneous administration · Time-to-event analysis · Hazard ratio · gastrointestinal adverse events · Clinically meaningful improvement · dual incretin receptor agonist
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459